A STUDY OF TS-1 IN PATIENTS WITH RECURRENT HEAD AND NECK CANCER-REGARD AS LUNG METASTASIS-:REGARD AS LUNG METASTASIS
スポンサーリンク
概要
- 論文の詳細を見る
A study of TS-1, a novel oral antitumor agent of fluorinated pyrimidines, in patients with recurrent head and neck cancer was conducted in 23 patients. Objective response was 1 complete response, for a response rate of 30.4%. Grade 4 thrombocytopenia and pneumonia were observed in one case; however, this returned to the normal level after the termination of drug administration and blood transfusion and steroid. There fore, this event was confirmed to be reversible. For patients with lung metastasis, median survival time was 585 days in the TS-1 group (n=6), and, 120 days in the conventional therapy group without TS-1 (n=6). The TS-1 method was useful from the point of view of QOL. Based on these results, we believe that TS-1 is an active agent for the treatment of recurrent or lung metastastic head and neck cancer.
- 日本頭頸部癌学会の論文
日本頭頸部癌学会 | 論文
- 口腔白板症に対する緑茶カテキンの治療効果に関する臨床的検討
- SUPERSELECTIVE ARTERIAL INFUSION AND CONCOMITANT RADIOTHERAPY FOR ADVANCED HEAD AND NECK CANCER
- MICROVASCULAR SURGERY IN HEAD AND NECK SURGERY
- タイトル無し
- タイトル無し